Effect of the Aquaretic Tolvaptan on Nitric Oxide System
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
Tolvaptan is a selective vasopressin receptor antagonist (V2R) that increases free water and
sodium excretion. Inhibition of V2R increases vasopressin concentration in plasma, which
stimulates V1-receptors in the vascular bed and may change both central and brachial
hemodynamics and plasma concentration of vasoactive hormones.
The purpose of the study is to measure the effects of tolvaptan on renal handling of water
and sodium, systemic hemodynamics and vasoactive hormones at baseline and during nitric oxide
(NO)-inhibition with L-NG-monomethyl-arginine (L-NMMA) in patients with autosomal dominant
polycystic kidney disease.